For patients still waiting, we can't just imagine better medicines. We have to build them. Our teams ask what's missing, then build what's next. Curious enough to keep looking, innovative enough to keep delivering. That's how ideas become impact. This is Ipsen. Make a real impact, every day. Learn more: https://lnkd.in/e5SmJaiU
About us
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
- Website
-
http://www.ipsen.com
External link for Ipsen
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Paris, Île-de-France
- Type
- Public Company
- Specialties
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins, and Primary Care
Locations
Employees at Ipsen
Updates
-
She knows exactly who her work is for. Because she's one of them. Rajminder Malhi is a Senior Customer Engagement Manager at Ipsen UK. She's also a patient. And after years of failed treatments that left her bed-bound, the right one gave her back the things most people take for granted: leaving the house, hugging her child. Now, every digital touchpoint she works on lands differently. Because she knows there's someone on the other end of it waiting for the same change she got. 💙 Learn more about Rajminder's story : https://lnkd.in/e5MrWaXH
-
Patients waiting for new medicines don't have time for hype cycles. The increasing complexity of modern science is the real reason pharma is talking about AI… but not every conversation is honest about what it can and can't yet do. So instead of claiming what AI will revolutionize, we're putting it to the experiment. A pilot with Claude for Healthcare & Life Sciences. Specialized AI built for scientific work, with governance and data protection built in from the start. We'll publish what we find. The good and the bad. Because patients deserve transparency, not empty promises. 💙 Learn more : https://lnkd.in/e2x5KpPz
-
We are pleased to complete the acquisition of Memo Therapeutics AG, further strengthening Ipsen's Rare Disease pipeline. This milestone reflects our commitment to advancing innovative medicines for patients with high unmet medical needs. Read more: https://lnkd.in/e2n4GBT7
-
-
What job fits this equation? 🧬 + 🔬 = 🚫 Meet Lindsey Rodrigues, Associate Director, Biological Sciences. A cancer biologist, she focuses on the hidden drivers of disease. At Ipsen, she leads early epigenetics research into how gene (🧬) activity shapes how cancer grows. Her work: spot which genes make a tumor tick (🔬), then design medicines to switch those genes off (🚫). Beyond the lab, she backs new ideas and mentors young scientists, believing every project should be one she’d trust for someone she loves. Grateful you’re on the team, Lindsey! Learn more about Lindsey : https://lnkd.in/eh6d5spX
-
-
Christelle Huguet, Ipsen’s Head of R&D, shares the latest research on the rare liver disease, primary biliary cholangitis (PBC).
-
-
The findings from a new Phase IIIb clinical trial contribute to ongoing research into biochemical outcomes associated with primary biliary cholangitis (PBC) disease progression. PBC is a rare, chronic liver disease, where disease progression can affect everyday life. Read the full press release: https://lnkd.in/e4iweB55
-
-
Patient organizations report 8.8 out of 10 engagement with Ipsen. A strong testament to relationships that are working well, built on trust, respect and long-term collaboration. As Aurora Berra MD PhD, VP Global Patient Officer highlights: “Our focus now is on deepening collaboration, moving toward more integrated, long-term relationships that ensure patient perspectives shape what we do at every stage.” Read more: https://lnkd.in/eDdWmuTS
-
-
These positive Phase III results represent an important step forward in advancing our understanding of migraine and its impact across diverse patient populations. Ipsen is proud to be part of the broader effort to advance science and support the development of new preventive treatment options that may help improve outcomes for people living with migraine.
-
-
Ipsen announces topline results from two Phase III trials in migraine prevention. Both studies met their primary endpoints. Read the full press release: https://lnkd.in/exeawfF2